De-escalation of Surgery for Melanoma

Stage II (Incl Neoadjuvant, no SLN)

Thursday, March 23, 2023

9:01 AM – 9:15 AM

Location: Ballroom C

Presenter(s)

Vernon K. Sondak, MD (he/him/his)

Chair, Department of Cutaneous Oncology
Moffitt Cancer Center
Tampa, Florida, United States

Disclosure(s): Alkermes: Independent Contractor (Ongoing); AmLO Biosciences: Advisor (Ongoing), Consultant (Ongoing); Bristol-Myers Squibb: Advisor (Ongoing), Consultant (Ongoing); Genesis Drug Discovery & Development: Independent Contractor (Ongoing); Iovance Biotherapeutics: Advisor (Ongoing), Consultant (Ongoing); Merck & Co., Inc.: Advisor (Ongoing), Consultant (Ongoing); Neogene Therapeutics: Research Grant (Ongoing); Novartis Pharmaceuticals Corporation: Advisor (Ongoing), Independent Contractor (Ongoing); Regeneron: Advisor (Ongoing), Consultant (Ongoing); SkylineDx: Research Grant (Ongoing); Turnstone Biologics: Contracted Research (Ongoing), Research Grant (Ongoing); Ultimovacs: Consultant (Ongoing)

Disclosure(s):

Vernon K. Sondak, MD: Alkermes: Independent Contractor (Ongoing); AmLO Biosciences: Advisor (Ongoing), Consultant (Ongoing); Bristol-Myers Squibb: Advisor (Ongoing), Consultant (Ongoing); Genesis Drug Discovery & Development: Independent Contractor (Ongoing); Iovance Biotherapeutics: Advisor (Ongoing), Consultant (Ongoing); Merck & Co., Inc.: Advisor (Ongoing), Consultant (Ongoing); Neogene Therapeutics: Research Grant (Ongoing); Novartis Pharmaceuticals Corporation: Advisor (Ongoing), Independent Contractor (Ongoing); Regeneron: Advisor (Ongoing), Consultant (Ongoing); SkylineDx: Research Grant (Ongoing); Turnstone Biologics: Contracted Research (Ongoing), Research Grant (Ongoing); Ultimovacs: Consultant (Ongoing)